Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Stem Cells and Eye Research Laboratory, Department of Ophthalmology, Faculty of Medicine, Albert Szent-Gyorgyi Clinical Center, University of Szeged, Szeged, Hungary.
Acta Ophthalmol. 2018 Aug;96(5):503-509. doi: 10.1111/aos.13645. Epub 2018 Jan 16.
Nestin, a member of the intermediate filament protein family, has been described as a putative cancer stem cell marker (CSC) in uveal melanoma and poor prognostic factor in a variety of tumours, including cutaneous melanoma. In this study, we examined the expression of nestin in primary (PUM) and metastatic uveal melanoma (MUM) samples, and correlated the findings with histological, clinical and survival data.
Nestin expression was assessed by immunohistochemistry in 141 PUM and 26 MUM samples; 11 PUM cases were matched with their corresponding metastases. The percentage of tumour cells expressing nestin was scored by three independent observers. Statistical analysis of all data was performed with SPSS.
Nestin expression was identified in both the cytoplasm and membrane of UM cells. Increased expression of nestin in PUM samples was associated with known poor prognostic parameters, including epithelioid cell morphology (p < 0.001), closed loops (p = 0.001), higher mitotic count (p < 0.001), monosomy 3 (p = 0.007) and chromosome 8q gain (p < 0.001). Primary uveal melanoma (PUM) with nestin expression levels above a cut-off value of 10% [as determined by receiver operating characteristic (ROC) analysis] was associated with a significantly reduced survival time (Log-rank, p = 0.002). In MUM, a higher percentage of nestin-positive tumour cells combined with poor prognostic markers in the PUM led to a shorter survival time following the development of metastases.
In conclusion, increased nestin expression in PUM is a predictor of a tumour phenotype associated with metastatic progression and reduced survival time at onset of metastasis.
巢蛋白是中间丝蛋白家族的一员,已被描述为葡萄膜黑色素瘤中的癌干细胞标志物(CSC)和多种肿瘤(包括皮肤黑色素瘤)中的不良预后因素。在这项研究中,我们检查了巢蛋白在原发性(PUM)和转移性葡萄膜黑色素瘤(MUM)样本中的表达,并将这些发现与组织学、临床和生存数据相关联。
通过免疫组织化学检测 141 例 PUM 和 26 例 MUM 样本中的巢蛋白表达;11 例 PUM 病例与其相应的转移灶相匹配。三位独立观察者对表达巢蛋白的肿瘤细胞百分比进行评分。所有数据的统计分析均采用 SPSS 进行。
在 UM 细胞的细胞质和膜中均发现巢蛋白表达。PUM 样本中巢蛋白表达增加与已知的不良预后参数相关,包括上皮样细胞形态(p<0.001)、封闭环(p=0.001)、较高的有丝分裂计数(p<0.001)、单体 3(p=0.007)和 8q 染色体增益(p<0.001)。巢蛋白表达水平超过 10%的原发性葡萄膜黑色素瘤(PUM)[通过接收者操作特征(ROC)分析确定]与生存时间显著缩短相关(对数秩,p=0.002)。在 MUM 中,PUM 中巢蛋白阳性肿瘤细胞比例较高,加上 PUM 中的不良预后标志物,导致转移后生存时间缩短。
总之,PUM 中巢蛋白表达增加是与转移进展相关的肿瘤表型的预测因子,并在转移发生时降低了生存时间。